August 3, 2009

Marlene H. Dortch Secretary Federal Communication Commission 445 12TH Street, SW Washington, D.C. 20554

RE: Amendment of parts 2 and 95 of the Commission's rules to Provide Additional Spectrum for the Medical Device Radiocommunication Service in the 413-457 MHZ Band (ET Dkt. No. 09-36;RM-11404)

Dear Ms Dortch:

I am submitting these comments to urge the Commission to adopt rules permitting the operation of medical micro-power network ("MMN") Devices in the 413-457MHz band.

I was part of a study that took place at Virginia Mason Hospital in Seattle from June 07 - June 08. A bion (battery-powered microstimulator) was implanted in my upper arm to help reduce pain and restore some function to an arm that was rendered flaccid and useless by a severe stroke I suffered in November of 03.

The bion did reduce the pain and allowed me to return to doing things I had eliminated from my life because of the pain. The bion also gave me back some usage of my affected arm. On one return trip from Seattle I was able to hug my wife with both arms for the first time in over four years (since I had my stroke).

I am familiar with the MMN devices that the Alfred Mann Foundation is developing, and I believe that these devices, if allowed to operate, will provide invaluable health benefits to millions of people suffering from strokes and debilitating conditions. Specifically, these MMN devices are designed to operate as an artificial nervous system to restore sensation, mobility, and other functions to paralyzed and paretic limbs and organs. They can be used to treat a broad range of injuries and conditions, including severe spinal cord and brain injuries, debilitating disorders such as cerebral palsy and osteoporosis, and more common afflictions such as arthritis and headache.

Unlike any other medical treatment option available today, MMN devices offer a novel wireless solution that addresses the significant limitations in the previously available technologies. They provide a safer, less invasive, more convenient, and more effective treatment option than existing alternatives.

Because the benefits offered by MMN devices are immeasurable and cannot be replicated by

other existing technologies, I urge the Commission to act expeditiously to adopt the rules necessary to foster the development of this extraordinary technology.

Sincerely,

Gary Okrent